Fennec Pharmaceuticals Inc (FENC) - Net Assets
Based on the latest financial reports, Fennec Pharmaceuticals Inc (FENC) has net assets worth $-4.49 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($49.21 Million) and total liabilities ($53.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FENC cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.49 Million |
| % of Total Assets | -9.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | -120.2% |
| 10-Year Change | -1171.53% |
| Growth Volatility | 4807.21 |
Fennec Pharmaceuticals Inc - Net Assets Trend (1999–2024)
This chart illustrates how Fennec Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Fennec Pharmaceuticals Inc (FENC) total assets for the complete picture of this company's asset base.
Annual Net Assets for Fennec Pharmaceuticals Inc (1999–2024)
The table below shows the annual net assets of Fennec Pharmaceuticals Inc from 1999 to 2024. For live valuation and market cap data, see Fennec Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-5.87 Million | +49.48% |
| 2023-12-31 | $-11.62 Million | -352.39% |
| 2022-12-31 | $-2.57 Million | -116.29% |
| 2021-12-31 | $15.77 Million | -45.74% |
| 2020-12-31 | $29.07 Million | +144.80% |
| 2019-12-31 | $11.88 Million | -44.28% |
| 2018-12-31 | $21.31 Million | -20.35% |
| 2017-12-31 | $26.76 Million | +649.50% |
| 2016-12-31 | $3.57 Million | +551.46% |
| 2015-12-31 | $548.00K | -10.60% |
| 2014-12-31 | $613.00K | +142.13% |
| 2013-12-31 | $-1.46 Million | +70.65% |
| 2012-12-31 | $-4.96 Million | -4030.83% |
| 2011-12-31 | $-120.00K | +97.56% |
| 2010-12-31 | $-4.92 Million | -1312.81% |
| 2009-12-31 | $406.00K | -86.70% |
| 2008-12-31 | $3.05 Million | -78.42% |
| 2007-12-31 | $14.15 Million | +86.53% |
| 2006-12-31 | $7.58 Million | -62.18% |
| 2005-12-31 | $20.06 Million | -39.23% |
| 2003-12-31 | $33.00 Million | +115.55% |
| 2002-12-31 | $15.31 Million | +151.79% |
| 2001-12-31 | $6.08 Million | -38.08% |
| 2000-12-31 | $9.82 Million | +20912.98% |
| 1999-12-31 | $46.73K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fennec Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21667347500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $145.61 Million | % |
| Other Comprehensive Income | $1.24 Million | % |
| Other Components | $66.96 Million | % |
| Total Equity | $-5.87 Million | 100.00% |
Fennec Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Fennec Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Teamlease Services Limited
NSE:TEAMLEASE
|
$223.41 Million |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IS:DOBUR
|
$223.42 Million |
|
Datawalk SA
WAR:DAT
|
$223.45 Million |
|
GD Culture Group Limited
NASDAQ:GDC
|
$223.54 Million |
|
Trisul S.A
SA:TRIS3
|
$223.14 Million |
|
Churchill Capital Corp X Class A Ordinary Shares
NASDAQ:CCCX
|
$223.09 Million |
|
Foraco International SA
TO:FAR
|
$223.08 Million |
|
GE Power India Limited
NSE:GEPIL
|
$222.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fennec Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -11,622,000 to -5,872,000, a change of 5,750,000.
- Net loss of 436,000 reduced equity.
- Share repurchases of 176,000 reduced equity.
- Other comprehensive income decreased equity by 1.
- Other factors increased equity by 6,362,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-436.00K | -7.43% |
| Share Repurchases | $176.00K | -3.0% |
| Other Comprehensive Income | $-1.00 | -0.0% |
| Other Changes | $6.36 Million | +108.34% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Fennec Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $0.09 | $6.54 | x |
| 2000-12-31 | $16.18 | $6.54 | x |
| 2001-12-31 | $6.32 | $6.54 | x |
| 2002-12-31 | $49.45 | $6.54 | x |
| 2003-12-31 | $56.83 | $6.54 | x |
| 2005-12-31 | $13.53 | $6.54 | x |
| 2006-12-31 | $5.12 | $6.54 | x |
| 2007-12-31 | $5.06 | $6.54 | x |
| 2008-12-31 | $0.99 | $6.54 | x |
| 2009-12-31 | $0.13 | $6.54 | x |
| 2010-12-31 | $-0.70 | $6.54 | x |
| 2011-12-31 | $-0.01 | $6.54 | x |
| 2012-12-31 | $-0.59 | $6.54 | x |
| 2013-12-31 | $-0.14 | $6.54 | x |
| 2014-12-31 | $0.06 | $6.54 | x |
| 2015-12-31 | $0.05 | $6.54 | x |
| 2016-12-31 | $0.28 | $6.54 | x |
| 2017-12-31 | $1.78 | $6.54 | x |
| 2018-12-31 | $1.12 | $6.54 | x |
| 2019-12-31 | $0.60 | $6.54 | x |
| 2020-12-31 | $1.23 | $6.54 | x |
| 2021-12-31 | $0.61 | $6.54 | x |
| 2022-12-31 | $-0.10 | $6.54 | x |
| 2023-12-31 | $-0.44 | $6.54 | x |
| 2024-12-31 | $-0.22 | $6.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fennec Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.92%
- • Asset Turnover: 1.06x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-244.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -3418.02% | -234898529.41% | 0.00x | 13.76x | $-1.60 Million |
| 2000 | -25.00% | -371917890.91% | 0.00x | 1.06x | $-3.44 Million |
| 2001 | -61.17% | 0.00% | 0.00x | 1.12x | $-4.33 Million |
| 2002 | -40.15% | 0.00% | 0.00x | 1.68x | $-7.68 Million |
| 2003 | -26.47% | 0.00% | 0.00x | 1.26x | $-12.04 Million |
| 2005 | -95.95% | 0.00% | 0.00x | 1.42x | $-21.25 Million |
| 2006 | -251.85% | 0.00% | 0.00x | 2.19x | $-19.86 Million |
| 2007 | -94.41% | 0.00% | 0.00x | 1.22x | $-14.77 Million |
| 2008 | -445.46% | 0.00% | 0.00x | 1.98x | $-13.91 Million |
| 2009 | -741.87% | 0.00% | 0.00x | 2.05x | $-3.05 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.33 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $4.70 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.67 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $1.99 Million |
| 2014 | -354.98% | 0.00% | 0.00x | 3.87x | $-2.24 Million |
| 2015 | -120.26% | 0.00% | 0.00x | 1.86x | $-713.80K |
| 2016 | -78.12% | 0.00% | 0.00x | 1.11x | $-3.15 Million |
| 2017 | -26.33% | 0.00% | 0.00x | 1.06x | $-9.72 Million |
| 2018 | -46.39% | 0.00% | 0.00x | 1.08x | $-12.02 Million |
| 2019 | -104.93% | 0.00% | 0.00x | 1.19x | $-13.65 Million |
| 2020 | -62.29% | -10652.35% | 0.01x | 1.08x | $-21.02 Million |
| 2021 | -109.01% | -10113.75% | 0.01x | 1.42x | $-18.77 Million |
| 2022 | 0.00% | -1544.89% | 0.05x | 0.00x | $-22.52 Million |
| 2023 | 0.00% | -75.50% | 0.79x | 0.00x | $-14.88 Million |
| 2024 | 0.00% | -0.92% | 1.06x | 0.00x | $151.20K |
Industry Comparison
This section compares Fennec Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fennec Pharmaceuticals Inc (FENC) | $-4.49 Million | -3418.02% | N/A | $223.36 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly … Read more